Lund Arthritis Research Group (LARG)
1 – 10 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
2024) In ACR Open Rheumatology(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
(
- Contribution to journal › Article
-
Mark
Belonging, happiness, freedom and empowerment-a qualitative study of patients' understanding of health in early rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy : results from the ICEBIO registry
2024) In Scandinavian Journal of Rheumatology(
- Contribution to journal › Article
-
Mark
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
(
- Contribution to journal › Article
-
Mark
Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients
(
- Contribution to journal › Article
- 2023
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
(
- Contribution to journal › Article
-
Mark
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
(
- Contribution to journal › Article
-
Mark
The effect of a tight control regime with monthly follow-up on remission rates and reported pain in early rheumatoid arthritis
(
- Contribution to journal › Article